Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3110.

https://doi.org/10.1182/blood.V128.22.3110.3110

Published: 2016

Journal Articles

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ronald Paquette, MD, Jason R. Gotlib, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Peter Langmuir, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3118.

https://doi.org/10.1182/blood.V128.22.3118.3118

Published: 2016

Journal Articles

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Alessandro M. Vannucchi, MD, Heinz Gisslinger, MD, Claire N. Harrison, Haifa Kathrin Al-Ali, MD, Ester Pungolino, MD, Jean-Jacques Kiladjian, MD PhD, Francoise Boyer-Perrard, MD, Franck E. Nicolini, MD PhD, Shuyuan Mo, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Peter A. te Boekhorst

Blood (2015) 126 (23): 2817.

https://doi.org/10.1182/blood.V126.23.2817.2817

Published: 2015

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study

Simon T Durrant, Arnon Nagler, Alessandro M Vannucchi, David Lavie, MD, Charles Chuah, Francesco Passamonti, Heinz Gisslinger, MD, Philipp le Coutre, Prashanth Gopalakrishna, MBBS, MRCS, Bruyère Mahuzier, Shuyuan Mo, Joaquin Martinez-Lopez

Blood (2015) 126 (23): 827.

https://doi.org/10.1182/blood.V126.23.827.827

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD

Blood (2015) 126 (23): 4060.

https://doi.org/10.1182/blood.V126.23.4060.4060

Published: 2015

Journal Articles

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Elizabeth O. Hexner, MD, Haifa Kathrin Al-Ali, MD, Lynda Foltz, MD FRCP, Michael Montgomery, MD, Wei Peng, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Hagop Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 1604.

https://doi.org/10.1182/blood.V126.23.1604.1604

Published: 2015

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

Celine Sarr, PhD, Shweta Urva, PhD, Jerry Nedelman, PhD, William Sallas, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Dany Habr, MD, Renaud Capdeville, MD

Blood (2014) 124 (21): 3228.

https://doi.org/10.1182/blood.V124.21.3228.3228

Published: 2014

Journal Articles

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Simon Durrant, MD, Maya Koren-Michowitz, MD, David Lavie, Joaquin Martinez-Lopez, MD PhD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Dana Iommazzo, Prashanth Gopalakrishna, MBBS, MRCS, Heinz Gisslinger, MD

Blood (2014) 124 (21): 710.

https://doi.org/10.1182/blood.V124.21.710.710

Published: 2014

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

Peter te Boekhorst, MD PhD, Claire N. Harrison, DM, FRCP, FRCPath, Heinz Gisslinger, MD PhD, Dietger Niederwieser, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1841.

https://doi.org/10.1182/blood.V124.21.1841.1841

Published: 2014

Journal Articles

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Haifa Kathrin Al-Ali, MD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Julian Perez Ronco, MD MBA, Lynda M Foltz, MD FRCP

Blood (2014) 124 (21): 4583.

https://doi.org/10.1182/blood.V124.21.4583.4583

Published: 2014

NARROW

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only